secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2025-10-22T23:59:59+00:00
Accession:  0001104659-25-101447
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata AP-SA02 phage cocktail hits primary endpoint in Phase 2a S. aureus bacteremia trial
--------------------------------------------------------------------------------

- Day 12 clinical response 88% AP-SA02 vs 58% placebo (p=0.047) by blinded investigators; 83% vs 58% by adjudication committee.
- Zero non-response/relapse in AP-SA02 arm at one week post-BAT and EOS vs ~25% placebo (p<0.025).
- AP-SA02 well-tolerated; no serious adverse events related to study drug; TEAEs 6% AP-SA02 vs 0% placebo.
- Armata plans to initiate a pivotal Phase 3 superiority trial in 2026, subject to FDA feedback.
- Defined phage variants in AP-SA02 show intrinsic adaptive mechanism to patient isolates, may enhance efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465925101447/0001104659-25-101447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465925101447/tm2529060d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-101447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer